Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 4/2011

01-08-2011 | Original Paper

Genetic profile of adenoid cystic carcinomas (ACC) with high-grade transformation versus solid type

Authors: Ana Flávia Costa, Albina Altemani, Hedy Vékony, Elisabeth Bloemena, Florentino Fresno, Carlos Suárez, José Luis Llorente, Mario Hermsen

Published in: Cellular Oncology | Issue 4/2011

Login to get access

Abstract

Background

ACC can occasionally undergo dedifferentiation also referred to as high-grade transformation (ACC-HGT). However, ACC-HGT can also undergo transformation to adenocarcinomas which are not poorly differentiated. ACC-HGT is generally considered to be an aggressive variant of ACC, even more than solid ACC. This study was aimed to describe the genetic changes of ACC-HGT in relation to clinico-pathological features, and to compare results to solid ACC.

Methods

Genome wide DNA copy number changes were analyzed by microarray CGH in ACC-HGT, four with transformation into moderately differentiated adenocarcinoma (MDA) and two into poorly differentiated carcinoma (PDC), and five solid ACC. In addition, Ki67 index and p53 immunopositivity was assessed.

Results

ACC-HGT carried fewer copy number changes compared to solid ACC. Two ACC-HGT cases harboured a breakpoint at 6q23, near the cMYB oncogene. The complexity of the genomic profile concurred with the clinical course of the patient. Among the ACC-HGT, p53 positivity significantly increased from the conventional to the transformed (both MDA and PDC) component.

Conclusion

ACC-HGT may not necessarily reflect a more advanced stage of tumor progression, but rather a transformation to another histological form in which the poorly differentiated forms (PDC) presents a genetic complexity similar to the solid ACC.
Literature
1.
A.K. El-Naggar, A.G. Huvos, Adenoid cystic carcinoma, in World Organization Classification of Tumors. Pathology & Genetics Head and Neck Tumours, ed. by L. Barnes, J.W. Everson, P. Reichart et al. (IARC Press, Lyon, 2005), pp. 221–222
2.
K.H. Perzin, P. Gullane, A.C. Clairmont, Adenoid cystic carcinomas arising in salivary glands: a correlation of histologic features and clinical course. Cancer 42, 265–282 (1978)PubMedCrossRef
3.
P.A. Szanto, M.A. Luna, M.E. Tortoledo et al., Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer 54, 1062–1069 (1984)PubMedCrossRef
4.
D.E. da Cruz Perez, F. de Abreu Alves, I. Nobuko Nishimoto et al., Prognostic factors in head and neck adenoid cystic carcinoma. Oral Oncol 42, 139–146 (2005)PubMedCrossRef
5.
G. Franzén, S. Nordgård, M. Boysen et al., DNA content in adenoid cystic carcinomas. Head Neck 17, 49–55 (1995)PubMedCrossRef
6.
H. Papadaki, S.D. Finkelstein, S. Kounelis et al., The role of p53 mutation and protein expression in primary and recurrent adenoid cystic carcinoma. Hum Pathol 27, 567–572 (1996)PubMedCrossRef
7.
T. Nagao, T.A. Gaffey, H. Serizawa et al., Dedifferentiated adenoid cystic carcinoma: a clinicopathologic study of 6 cases. Mod Pathol 16, 1265–1272 (2003)PubMedCrossRef
8.
F. Ide, K. Mishima, I. Saito, Small foci of high-grade carcinoma cells in adenoid cystic carcinoma represent an incipient phase of dedifferentiation. Histopathology 43, 604–606 (2003)PubMedCrossRef
9.
Y. Chau, T. Hongyo, K. Aozasa et al., Dedifferentiation of adenoid cystic carcinoma: report of a case implicating p53 gene mutation. Hum Pathol 32, 1403–1407 (2001)PubMedCrossRef
10.
M.A. Moles, I.R. Avila, A.R. Archilla, Dedifferentiation occurring in adenoid cystic carcinoma of the tongue. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88, 177–180 (1999)PubMedCrossRef
11.
W. Cheuk, J.K. Chan, R.K. Ngan, Dedifferentiation in adenoid cystic carcinoma of salivary gland: an uncommon complication associated with an accelerated clinical course. Am J Surg Pathol 23, 465–472 (1999)PubMedCrossRef
12.
K. Sato, Y. Ueda, A. Sakurai et al., Adenoid cystic carcinoma of the maxillary sinus with gradual histologic transformation to high-grade adenocarcinoma: a comparative report with dedifferentiated carcinoma. Virchows Arch 448, 204–208 (2006)PubMedCrossRef
13.
R.R. Seethala, J.L. Hunt, Z.W. Baloch et al., Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and a review of the literature. Am J Surg Pathol 31, 1683–1694 (2007)PubMedCrossRef
14.
A. Handra-Luca, D. Planchard, P. Fouret, Docetaxel-cisplatin-radiotherapy in adenoid cystic carcinoma with high-grade transformation. Oral Oncol 45, 208–209 (2009)CrossRef
15.
K.P. Malhotra, V. Agrawal, R. Pandey, High grade transformation in adenoid cystic carcinoma of the parotid: report of a case with cytologic, histologic and immunohistochemical study. Head Neck Pathol 3, 310–314 (2009)PubMedCrossRef
16.
V.L. Bonfitto, A.P. Demasi, A.F. Costa et al., High-grade transformation of adenoid cystic carcinomas may result in adenocarcinomas with wide spectrum of differentiation. A study of the expression of GLUT1 glucose transporter and of mitochondrial antigen in the transformed component. J Clin Pathol 63, 615–619 (2010)PubMedCrossRef
17.
H. Vékony, B. Ylstra, S.M. Wilting et al., DNA copy number gains at loci of growth factors and their receptors in salivary gland adenoid cystic carcinoma. Clin Cancer Res 13, 3133–3139 (2007)PubMedCrossRef
18.
B.M. Wening, Neoplasmas of the salivary glands, in Atlas of head and neck pathology, ed. by B.M. Wening, C.S. Heffess (China, Saunders Elsevier, 2008), pp. 628–631
19.
T.E. Buffart, D. Israeli, M. Tijssen et al., Across array comparative genomic hybridization: a strategy to reduce reference channel hybridizations. Genes Chromosom Cancer 47, 994–1004 (2008)PubMedCrossRef
20.
G. Stenman, J. Sandros, R. Dahlenfors et al., 6q- and loss of the Y chromosome–two common deviations in malignant human salivary gland tumors. Cancer Genet Cytogenet 22, 283–293 (1986)PubMedCrossRef
21.
K. Higashi, Y. Jin, M. Johansson et al., Rearrangement of 9p13 as the primary chromosomal aberration in adenoid cystic carcinoma of the respiratory tract. Genes Chromosom Cancer 3, 21–23 (1991)PubMedCrossRef
22.
A. Nordkvist, J. Mark, H. Gustafsson et al., Non-random chromosome rearrangements in adenoid cystic carcinoma of the salivary glands. Genes Chromosom Cancer 10, 115–121 (1994)PubMedCrossRef
23.
L. Queimado, A. Reis, I. Fonseca et al., A refined localization of two deleted regions in chromosome 6q associated with salivary gland carcinomas. Oncogene 16, 83–88 (1998)PubMedCrossRef
24.
M. Kishi, M. Nakamura, M. Nishimine et al., Loss of heterozygosity on chromosome 6q correlates with decreased thrombospondin-2 expression in human salivary gland carcinomas. Cancer Sci 94, 530–535 (2003)PubMedCrossRef
25.
W. El-Rifai, S. Rutherford, S. Knuutila et al., Novel DNA copy number losses in chromosome 12q12–q13 in adenoid cystic carcinoma. Neoplasia 3, 173–178 (2001)PubMedCrossRef
26.
R.H. Rao, D. Roberts, Y.J. Zhao et al., Deletion of 1p32-p36 is the most frequent genetic change and poor prognostic marker in adenoid cystic carcinoma of the salivary glands. Clin Cancer Res 14, 5181–5187 (2008)PubMedCrossRef
27.
I. Stallmach, P. Zenklusen, P. Komminoth et al., Loss of heterozygosity at chromosome 6q23-25 correlates with clinical and histologic parameters in salivary gland adenoid cystic carcinoma. Virchows Arch 440, 77–84 (2002)PubMedCrossRef
28.
S. Rutherford, Y. Yu, C.A. Rumpel et al., Chromosome 6 deletion and candidate tumor suppressor genes in adenoid cystic carcinoma. Cancer Lett 236, 309–317 (2006)PubMedCrossRef
29.
J.M. Geurts, E.F. Schoenmakers, E. Röijer et al., Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene 16, 865–872 (1998)PubMedCrossRef
30.
M. Persson, Y. Andrén, J. Mark et al., Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 106, 18740–18744 (2009)PubMedCrossRef
31.
E. Kennah, A. Ringrose, L.L. Zhou et al., Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells. Blood 113, 4646–4655 (2009)PubMedCrossRef
32.
L.L. Zhou, Y. Zhao, A. Ringrose et al., AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells. J Exp Med 205, 2657–2671 (2008)PubMedCrossRef
33.
T. Soussi, The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci 910, 121–137 (2000)PubMedCrossRef
Metadata
Title
Genetic profile of adenoid cystic carcinomas (ACC) with high-grade transformation versus solid type
Authors
Ana Flávia Costa
Albina Altemani
Hedy Vékony
Elisabeth Bloemena
Florentino Fresno
Carlos Suárez
José Luis Llorente
Mario Hermsen
Publication date
01-08-2011
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 4/2011
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-011-0037-5

Other articles of this Issue 4/2011

Cellular Oncology 4/2011 Go to the issue

Original Paper

Dual effects of β3 integrin subunit expression on human pancreatic cancer models

Original Paper

Rapid quantification of myocardial fibrosis: a new macro-based automated analysis

Original Paper

The GNAS1 T393C single nucleotide polymorphism predicts the natural postoperative course of complete resected esophageal cancer

Original Paper

High Acute Myeloid Leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow

Original Paper

Tumor necrosis factor-α is associated with positive lymph node status in patients with recurrence of colorectal cancer—indications for anti-TNF-α agents in cancer treatment

Original Paper

TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits